Is it possible to predict HCV-related liver cirrhosis through routine laboratory parameters?;É possibile predire la cirrosi epatica HCV-correlata attraverso parametri laboratoristici di routine?

Infezioni in Medicina

Volumn 22, Issue 1, 2014, Pages 11-18

  Gentile, Ivan ^a   Buonomo, Antonio Riccardo ^a   Zappulo, Emanuela ^a   Borgia, Guglielmo ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BOCEPREVIR; PEGINTERFERON; PROTHROMBIN; RIBAVIRIN; TELAPREVIR;

ALCOHOL CONSUMPTION; ASCITES; BLEEDING; CLINICAL TRIAL (TOPIC); END STAGE LIVER DISEASE; ENDOSCOPY; ESOPHAGUS VARICES; FIBROSIS; GENETIC HETEROGENEITY; HEPATITIS; HEPATITIS B VIRUS; HEPATITIS C VIRUS; HISTOLOGY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE SYSTEM; IRON OVERLOAD; JAUNDICE; LABORATORY TEST; LIVER BIOPSY; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; PREDICTIVE VALUE; REVIEW; STEATOSIS; ULTRASOUND; CHRONIC HEPATITIS C; COMPLICATION; DIAGNOSTIC PROCEDURE; DIAGNOSTIC TEST;

CLINICAL LABORATORY TECHNIQUES; DIAGNOSTIC TESTS, ROUTINE; HEPATITIS C, CHRONIC; HUMANS; LIVER CIRRHOSIS; PREDICTIVE VALUE OF TESTS;

EID: 84897421294     PISSN: 11249390     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (83)

1. Perz J.F., Armstrong G.L., Farrington L.A., Hutin Y.J., Bell B.P. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J. Hepatol. 45, 529-538, 2006.
2. Lavanchy D. Evolving epidemiology of hepatitis C virus. Clin. Microbiol. Infect. 17, 107-115, 2011.
3. Smith D.B., Bukh J., Kuiken C., et al. Expanded classification of hepatitis C Virus into 7 genotypes and 67 Subtypes: updated criteria and assignment web resource. Hepatology 1, 318-327, 2013.
4. Gentile I., Di Flumeri G., Scarica S., et al. Acute hepatitis C in patients undergoing hemodialysis: experience with high-dose interferon therapy. Minerva Urol. Nefrol. 65, 83-84, 2013.
5. Gentile I., De Stefano A., Di Flumeri G., et al. Concomitant interferon-alpha and chemotherapy in hepatitis C and colorectal cancer: a case report. In Vivo 27, 527-529, 2013.
6. Carney K., Dhalla S., Aytaman A., Tenner C.T., Francois F. Association of tattooing and hepatitis C virus infection: a multicenter case-control study. Hepatology 57, 2117-2123, 2013.
7. Coppola N., Pisapia R., Tonziello G., et al. Improvement in the aetiological diagnosis of acute hepatitis C: a diagnostic protocol based on the anti-HCV-IgM titre and IgG Avidity Index. J. Clin. Virol. 46, 222-229, 2009.
8. Coppola N., Pisapia R., Marrocco C., et al. Anti-HCV IgG avidity index in acute hepatitis C. J. Clin. Virol. 40, 110-115, 2007.
9. Davis G.L., Alter M.J., El-Serag H., Poynard T., Jennings L.W. Aging of hepatitis C virus (HCV)-infected persons in the United States: a multiple cohort model of HCV prevalence and disease progression. Gastroenterology 138, 513-521, 2010.
10. Gentile I., Viola C., Graf M., et al. A simple noninvasive score predicts gastroesophageal varices in patients with chronic viral hepatitis. J. Clin. Gastroenterol. 43, 81-87, 2009.
11. Petruzziello A., Coppola N., Diodato A.M., et al. Age and gender distribution of hepatitis C virus genotypes in the metropolitan area of Naples. Intervirology 56, 206-212, 2013.
12. Hoofnagle J.H. Hepatitis C: the clinical spectrum of disease. Hepatology 26, 15S-20S, 1997.
13. Piazza M. Epatite Virale Acuta e Cronica. IX ed. 2009 Naples, Ghedini s.a.s.
14. Maasoumy B., Wedemeyer H. Natural history of acute and chronic hepatitis C. Best Pract. Res. Clin. Gastroenterol. 26, 401-412, 2012.
15. Sagnelli E., Pisaturo M., Stanzione M., et al. Clinical presentation, outcome, and response to therapy among patients with acute exacerbation of chronic hepatitis C. Clin. Gastroenterol. Hepatol. 11, 1174-1180, 2013.
16. Coppola N., Gentile I., Pasquale G., et al. Anti-HBc positivity was associated with histological cirrhosis in patients with chronic hepatitis C. Ann. Hepatol. 13, 20-26, 2014.
17. Fortunato G., Calcagno G., Bresciamorra V., et al. Multiple sclerosis and hepatitis C virus infection are associated with single nucleotide polymorphisms in interferon pathway genes. J. Interferon Cytokine Res. 28, 141-152, 2008.
18. Fortunato G., Castaldo G., Oriani G., et al. Multivariate discriminant function based on six biochemical markers in blood can predict the cirrhotic evolution of chronic hepatitis. Clin. Chem. 47, 1696-1700, 2001.
19. Gentile I., Meola M., Buonomo A.R., et al. Human platelet antigen-3 genotype predicts platelet count in patients with HCV infection. In Vivo 27, 773-777, 2013.
20. Coppola N., Zampino R., Bellini G., et al. Association between a polymorphism in cannabinoid receptor 2 and severe necroinflammation in patients with chronic hepatitis C. Clin. Gastroenterol. Hepatol. 12, 334-340, 2014.
21. Sagnelli E., Stroffolini T., Mele A., et al. The importance of HCV on the burden of chronic liver disease in Italy: a multicenter prevalence study of 9,997 cases. J. Med. Virol. 75, 522-527, 2005.
22. Guadagnino V., Stroffolini T., Caroleo B., et al. Hepatitis C virus infection in an endemic area of Southern Italy 14 years later: evidence for a vanishing infection. Dig. Liver Dis. 45, 403-407, 2013.
23. Guadagnino V., Stroffolini T., Rapicetta M., et al. Prevalence, risk factors, and genotype distribution of hepatitis C virus infection in the general population: a community-based survey in southern Italy. Hepatology 26, 1006-1011, 1997.
24. Ferrari S.M., Fallahi P., Mancusi C., et al. HCVrelated autoimmune disorders in HCV chronic infection. Clin. Ter. 164, e305-e312, 2013.
25. Coppola N., Pisaturo M., Guastafierro S., et al. Increased hepatitis C viral load and reactivation of liver disease in HCV RNA-positive patients with onco-haematological disease undergoing chemotherapy. Dig. Liver Dis. 44, 49-54, 2012.
26. Zampino R., Coppola N., Cirillo G. et al. Abdominal fat interacts with PNPLA3 I148M, but not with the APOC3 variant in the pathogenesis of liver steatosis in chronic hepatitis C. J. Viral Hepat. 20, 8, 517-523, 2013.
27. Coppola N., Pascalis S.D., Pisaturo M., et al. Sustained virological response to antiviral treatment in chronic hepatitis C patients may be predictable by HCV-RNA clearance in peripheral blood mononuclear cells. J. Clin. Virol. S1386-S1653, 2013.
28. Fusco F., D'Anzeo G., Rossi A., et al. Erectile dysfunction in patients with chronic viral hepatitis: a systematic review of the literature. Expert Opin. Pharmacother. 14, 2533-2544, 2013.
29. Gentile I., Borgia G. Prediction of liver cirrhosis in patients with HCV chronic infection through routine laboratory parameters: myth or reality? J. Mol. Genet. Med. 7, 76, 2013.
30. Gentile I., Borgia G. Surrogate endpoints and non-inferiority trials in chronic viral hepatitis. J. Hepatol. 52, 778, 2010.
31. Braks R.E., Ganne-Carrie N., Fontaine H., et al. Effect of sustained virological response on long-term clinical outcome in 113 patients with compensated hepatitis C-related cirrhosis treated by interferon alpha and ribavirin. World J. Gastroenterol. 13, 5648-5653, 2007.
32. Tsuda N., Yuki N., Mochizuki K., et al. Longterm clinical and virological outcomes of chronic hepatitis C after successful interferon therapy. J. Med. Virol. 74, 406-413, 2004.
33. Bruno S., Stroffolini T., Colombo M., et al. Sustained virological response to interferon-alpha is associated with improved outcome in HCV-related cirrhosis: a retrospective study. Hepatology 45, 579-587, 2007.
34. Di Marco V., Almasio P.L., Ferraro D., et al. Peginterferon alone or combined with ribavirin in HCV cirrhosis with portal hypertension: a randomized controlled trial. J. Hepatol. 47, 484-491, 2007.
35. Hermine O., Lefrere F., Bronowicki J.P., et al. Regression of splenic lymphoma with villous lymphocytes after treatment of hepatitis C virus infection. N. Engl. J. Med. 347, 89-94, 2002.
36. Takahashi K., Nishida N., Kawabata H., Haga H., Chiba T. Regression of Hodgkin lymphoma in response to antiviral therapy for hepatitis C virus infection. Intern. Med. 51, 2745-2747, 2012.
37. Venkatraman S., Bogen S.L., Arasappan A., et al. Discovery of (1R,5S)-N-[3-amino-1-(cyclobutylme-thyl)-2,3-dioxopropyl]-3-[2(S)-[(1,1-dimethylethyl)-amino]carbonyl]amino]-3,3-dimethyl-1-oxo butyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexan-2(S)-carboxamide (SCH 503034), a selective, potent, orally bioavailable hepatitis C virus NS3 protease inhibitor: a potential therapeutic agent for the treatment of hepatitis C infection. J. Med. Chem. 49, 6074-6086, 2006.
38. Tong X., Chase R., Skelton A., Chen T., Wright-Minogue J., Malcolm B.A. Identification and analysis of fitness of resistance mutations against the HCV protease inhibitor SCH 503034. Antiviral Res. 70, 28-38, 2006.
39. Lin C., Kwong A.D., Perni R.B. Discovery and development of VX-950, a novel, covalent, and reversible inhibitor of hepatitis C virus NS3.4A serine protease. Infect. Disord. Drug Targets 6, 3-16, 2006.
40. Gentile I., Viola C., Borgia F., Castaldo G., Borgia G. Telaprevir: a promising protease inhibitor for the treatment of hepatitis C virus infection. Curr. Med. Chem. 16, 1115-1121, 2009.
41. Coppola N., Pisaturo M., Tonziello G., Sagnelli C., Sagnelli E., Angelillo I.F. Efficacy of Pegylated interferon alpha-2a and alpha-2b in patients with genotype 1 chronic hepatitis C: a meta-analysis. BMC Infect. Dis. 12, 1471-2334, 2012.
42. Ghany M.G., Strader D.B., Thomas D.L., Seeff L.B. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 49, 1335-1374, 2009.
43. Morisco F., Granata R., Stroffolini T., et al. Sustained virological response: A milestone in the treatment of chronic hepatitis C. World J. Gastroenterol. 19, 2793-2798, 2013.
44. Chen J., Florian J., Carter W., et al. Earlier sustained virologic response end points for regulatory approval and dose selection of hepatitis C therapies. Gastroenterology 144, 1450-1455, 2013.
45. Lange C.M., Bojunga J., Ramos-Lopez E., et al. Vitamin D deficiency and a CYP27B1-1260 promoter polymorphism are associated with chronic hepatitis C and poor response to interferon-alfa based therapy. J. Hepatol. 54, 887-893, 2011.
46. Ismail M.H. Prediction of sustained virologic responses to combination therapy of pegylated interferon-alpha and ribavirin in patients with chronic hepatitis C infection. J. Family Community Med. 20, 35-40, 2013.
47. Borgia G., Gentile I., Fortunato G., et al. Homocysteine levels and sustained virological response to pegylated-interferon alpha2b plus ribavirin therapy for chronic hepatitis C: a prospective study. Liver Int. 29, 248-252, 2009.
48. Distante S., Bjoro K., Hellum K.B., et al. Raised serum ferritin predicts non-response to interferon and ribavirin treatment in patients with chronic hepatitis C infection. Liver 22, 269-275, 2002.
49. Gentile I., Viola C., Paesano L., et al. Iron depletion before HCV antiviral therapy: a pilot, randomized, controlled trial. J. Clin. Apher. 24, 190-196, 2009.
50. Abu-Mouch S., Fireman Z., Jarchovsky J., Zeina A.R., Assy N. Vitamin D supplementation improves sustained virologic response in chronic hepatitis C (genotype 1)-naive patients. World J. Gastroenterol. 17, 5184-5190, 2011.
51. Nimer A., Mouch A. Vitamin D improves viral response in hepatitis C genotype 2-3 naive patients. World J. Gastroenterol. 18, 800-805, 2012.
52. Coppola N., Marrone A., Pisaturo M., et al. Role of interleukin 28-B in the spontaneous and treatment-related clearance of HCV infection in patients with chronic HBV/HCV dual infection. Eur. J. Clin. Microbiol. Infect. Dis. 33, 559-567, 2014.
53. Ghany M.G., Nelson D.R., Strader D.B., Thomas D.L., Seeff L.B. An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology 54, 1433-1444, 2011.
54. Gentile I., Viola C., Reynaud L., et al. Hemolytic anemia during pegylated IFN-alpha2b plus ribavirin treatment for chronic hepatitis C: ribavirin is not always the culprit. J. Interferon Cytokine Res. 25, 283-285, 2005.
55. Tosone G., Borgia G., Gentile I., et al. A case of pegylated interferon alpha-related diabetic ketoacidosis: can this complication be avoided? Acta Diabetol. 44, 167-169, 2007.
56. Gentile I., Borgia F., Coppola N., Buonomo A.R., Castaldo G., Borgia G. Daclatasvir: the first of a new class of drugs targeted against Hepatitis C Virus NS5A. Curr. Med. Chem. In press. PMID: 24372205
57. Gentile I., Borgia F., Buonomo A.R., Castaldo G., Borgia G. A novel promising therapeutic option against hepatitis C virus: an oral nucleotide NS5B polymerase inhibitor sofosbuvir. Curr. Med. Chem. 20, 3733-3742, 2013.
58. Sarrazin C., Hezode C., Zeuzem S., Pawlotsky J.M. Antiviral strategies in hepatitis C virus infection. J. Hepatol. 56, S88-S100, 2012.
59. Gentile I., Borgia F., Zappulo E., et al. Efficacy and safety of sofosbuvir in treatment of chronic hepatitis C: the dawn of the a new era. Rev. Recent Clin. Trials In press. PMID: 23859195
60. Stedman C.A. Current prospects for interferonfree treatment of hepatitis C in 2012. J. Gastroenterol. Hepatol. 28, 38-45, 2013.
61. Gentile I., Buonomo A.R., Borgia F., Castaldo G., Borgia G. Ledipasvir: a novel synthetic antiviral for the treatment of HCV Infection. Expert Opin. Investig. Drugs. 23, 561-571, 2014.
62. Tillmann H.L. Hepatitis C infection and presence of advanced fibrosis: wait or treat? Why wait? There is no time to lose, is there? J. Hepatol. 58, 412-414, 2013.
63. Cadranel J.F., Rufat P., Degos F. Practices of liver biopsy in France: results of a prospective nationwide survey. For the Group of Epidemiology of the French Association for the Study of the Liver (AFEF). Hepatology 32, 477-481, 2000.
64. Perrault J., McGill D.B., Ott B.J., Taylor W.F. Liver biopsy: complications in 1000 inpatients and outpatients. Gastroenterology 74, 103-106, 1978.
65. Sagnelli E., Sagnelli C., Pisaturo M.A., Coppola N., Pasquale G., Piccinino F. Liver biopsy in chronic hepatitis C: the experience of 15 Italian wards of infectious diseases. Infez. Med. 20, 31-36, 2012.
66. Janes C.H., Lindor K.D. Outcome of patients hospitalized for complications after outpatient liver biopsy. Ann. Intern. Med. 118, 96-98, 1993.
67. Martinez S.M., Crespo G., Navasa M., Forns X. Noninvasive assessment of liver fibrosis. Hepatology 53, 325-335, 2011.
68. Ziol M., Handra-Luca A., Kettaneh A., et al. Noninvasive assessment of liver fibrosis by measurement of stiffness in patients with chronic hepatitis C. Hepatology 41, 48-54, 2005.
69. Imbert-Bismut F., Ratziu V., Pieroni L., Charlotte F., Benhamou Y., Poynard T. Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study. Lancet 357, 1069-1075, 2001.
70. Lok A.S., Ghany M.G., Goodman Z.D., et al. Predicting cirrhosis in patients with hepatitis C based on standard laboratory tests: results of the HALT-C cohort. Hepatology 42, 282-292, 2005.
71. Islam S., Antonsson L., Westin J., Lagging M. Cirrhosis in hepatitis C virus-infected patients can be excluded using an index of standard biochemical serum markers. Scand. J. Gastroenterol. 40, 867-872, 2005.
72. Lackner C., Struber G., Liegl B., et al. Comparison and validation of simple noninvasive tests for prediction of fibrosis in chronic hepatitis C. Hepatology 41, 1376-1382, 2005.
73. Ohta T., Sakaguchi K., Fujiwara A., et al. Simple surrogate index of the fibrosis stage in chronic hepatitis C patients using platelet count and serum albumin level. Acta Med. Okayama 60, 77-84, 2006.
74. Sheth S.G., Flamm S.L., Gordon F.D., Chopra S. AST/ALT ratio predicts cirrhosis in patients with chronic hepatitis C virus infection. Am. J. Gastroenterol. 93, 44-48, 1998.
75. Wai C.T., Greenson J.K., Fontana R.J., et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology 38, 518-526, 2003.
76. Gentile I., Coppola N., Pasquale G., et al. A simple noninvasive score based on routine parameters can predict liver cirrhosis in patients with chronic Hepatitis C. Hepatitis Monthly 13, e8352, 2013.
77. Reedy D.W., Loo A.T., Levine R.A. AST/ALT ratio > or = 1 is not diagnostic of cirrhosis in patients with chronic hepatitis C. Dig. Dis. Sci. 43, 2156-2159, 1998.
78. Gentile I., Thabut D. Noninvasive prediction of oesophageal varices: as simple as blood count? Liver Int. 30, 1091-1093, 2010.
79. Poynard T., de Ledinghen V., Zarski J.P., et al. Relative performances of fibrotest, fibroscan, and biopsy for the assessment of the stage of liver fibrosis in patients with chronic hepatitis C: a step toward the truth in the absence of a gold standard. J. Hepatol. 56, 541-548, 2012.
80. Bedossa P., Dargere D., Paradis V. Sampling variability of liver fibrosis in chronic hepatitis C. Hepatology 38, 1449-1457, 2003.
81. Pagliaro L., Rinaldi F., Craxi A., et al. Percutaneous blind biopsy versus laparoscopy with guided biopsy in diagnosis of cirrhosis. A prospective, randomized trial. Dig. Dis. Sci. 28, 39-43, 1983.
82. Colloredo G., Guido M., Sonzogni A., Leandro G. Impact of liver biopsy size on histological evaluation of chronic viral hepatitis: the smaller the sample, the milder the disease. J. Hepatol. 39, 239-244, 2003.
83. Scheuer P.J. Liver biopsy size matters in chronic hepatitis: bigger is better. Hepatology 38, 1356-1358, 2003.